for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Indivior revenue falls as top opioid drug hit by competition, pandemic

Feb 18 (Reuters) - Opioid addiction treatment maker Indivior said on Thursday annual revenue fell 18%, hit by a decline in demand for its best-selling drug due to cheaper rivals and as patients stayed away from hospitals during the COVID-19 pandemic.

The company said revenue fell to $647 million in the 12 months ended Dec. 31, from $785 million a year ago. (Reporting by Pushkala Aripaka in Bengaluru; Editing by Sriraj Kalluvila)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up